444 related articles for article (PubMed ID: 38298192)
21. Role of integrated cancer nanomedicine in overcoming drug resistance.
Iyer AK; Singh A; Ganta S; Amiji MM
Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1784-802. PubMed ID: 23880506
[TBL] [Abstract][Full Text] [Related]
22. Drug delivery to the intestinal lymph by oral formulations.
Yoshida T; Kojima H; Sako K; Kondo H
Pharm Dev Technol; 2022 Feb; 27(2):175-189. PubMed ID: 35037843
[TBL] [Abstract][Full Text] [Related]
23. Lymphatic immunomodulation using engineered drug delivery systems for cancer immunotherapy.
Manspeaker MP; Thomas SN
Adv Drug Deliv Rev; 2020; 160():19-35. PubMed ID: 33058931
[TBL] [Abstract][Full Text] [Related]
24. Stimuli-responsive nanoparticles based on poly acrylic derivatives for tumor therapy.
Li K; Zang X; Cheng M; Chen X
Int J Pharm; 2021 May; 601():120506. PubMed ID: 33798689
[TBL] [Abstract][Full Text] [Related]
25. Opportunities in combinational chemo-immunotherapy for breast cancer using nanotechnology: an emerging landscape.
Raikwar S; Jain A; Saraf S; Bidla PD; Panda PK; Tiwari A; Verma A; Jain SK
Expert Opin Drug Deliv; 2022 Mar; 19(3):247-268. PubMed ID: 35184620
[TBL] [Abstract][Full Text] [Related]
26. Advances in herbal polysaccharides-based nano-drug delivery systems for cancer immunotherapy.
Han MM; Fan YK; Zhang Y; Dong ZQ
J Drug Target; 2024 Dec; 32(3):311-324. PubMed ID: 38269853
[TBL] [Abstract][Full Text] [Related]
27. Tailored Mesoporous Silica Nanoparticles for Controlled Drug Delivery: Platform Fabrication, Targeted Delivery, and Computational Design and Analysis.
She X; Chen L; Yi Z; Li C; He C; Feng C; Wang T; Shigdar S; Duan W; Kong L
Mini Rev Med Chem; 2018; 18(11):976-989. PubMed ID: 27145854
[TBL] [Abstract][Full Text] [Related]
28. Recent Advances in Asialoglycoprotein Receptor and Glycyrrhetinic Acid Receptor-Mediated and/or pH-Responsive Hepatocellular Carcinoma- Targeted Drug Delivery.
Li YL; Zhu XM; Liang H; Orvig C; Chen ZF
Curr Med Chem; 2021; 28(8):1508-1534. PubMed ID: 32368967
[TBL] [Abstract][Full Text] [Related]
29. Delivery strategies of cancer immunotherapy: recent advances and future perspectives.
Zhao Z; Zheng L; Chen W; Weng W; Song J; Ji J
J Hematol Oncol; 2019 Nov; 12(1):126. PubMed ID: 31779642
[TBL] [Abstract][Full Text] [Related]
30. Ultrasound-mediated nano drug delivery for treating cancer: Fundamental physics to future directions.
Moradi Kashkooli F; Jakhmola A; Hornsby TK; Tavakkoli JJ; Kolios MC
J Control Release; 2023 Mar; 355():552-578. PubMed ID: 36773959
[TBL] [Abstract][Full Text] [Related]
31. Aptamer-based ATP-responsive delivery systems for cancer diagnosis and treatment.
Sameiyan E; Bagheri E; Dehghani S; Ramezani M; Alibolandi M; Abnous K; Taghdisi SM
Acta Biomater; 2021 Mar; 123():110-122. PubMed ID: 33453405
[TBL] [Abstract][Full Text] [Related]
32. Nanotechnology based solutions for anti-leishmanial impediments: a detailed insight.
Jamshaid H; Din FU; Khan GM
J Nanobiotechnology; 2021 Apr; 19(1):106. PubMed ID: 33858436
[TBL] [Abstract][Full Text] [Related]
33. Recent Advances in Gelatin-Based Nanomedicine for Targeted Delivery of Anti-Cancer Drugs.
Raza F; Siyu L; Zafar H; Kamal Z; Zheng B; Su J; Qiu M
Curr Pharm Des; 2022; 28(5):380-394. PubMed ID: 34727851
[TBL] [Abstract][Full Text] [Related]
34. Advances in silica based nanoparticles for targeted cancer therapy.
Yang Y; Yu C
Nanomedicine; 2016 Feb; 12(2):317-32. PubMed ID: 26706409
[TBL] [Abstract][Full Text] [Related]
35. Study on the Effect and Mechanism of Paclitaxel-Succini Acid Drug-Loaded Nanofibers in Treating Lung Cancer.
Pan B; Li P; Chen J; Sun J; Huang N
J Nanosci Nanotechnol; 2021 Feb; 21(2):909-913. PubMed ID: 33183423
[TBL] [Abstract][Full Text] [Related]
36. Mesoporous silica nanoparticles: synthesis, classification, drug loading, pharmacokinetics, biocompatibility, and application in drug delivery.
Li Z; Zhang Y; Feng N
Expert Opin Drug Deliv; 2019 Mar; 16(3):219-237. PubMed ID: 30686075
[TBL] [Abstract][Full Text] [Related]
37. Polymeric micelles and cancer therapy: an ingenious multimodal tumor-targeted drug delivery system.
Hari SK; Gauba A; Shrivastava N; Tripathi RM; Jain SK; Pandey AK
Drug Deliv Transl Res; 2023 Jan; 13(1):135-163. PubMed ID: 35727533
[TBL] [Abstract][Full Text] [Related]
38. Advances in Therapeutic Implications of Inorganic Drug Delivery Nano-Platforms for Cancer.
Naz S; Shamoon M; Wang R; Zhang L; Zhou J; Chen J
Int J Mol Sci; 2019 Feb; 20(4):. PubMed ID: 30813333
[TBL] [Abstract][Full Text] [Related]
39. Insights on the Dynamic Innovative Tumor Targeted-Nanoparticles-Based Drug Delivery Systems Activation Techniques.
Hamdy NM; Eskander G; Basalious EB
Int J Nanomedicine; 2022; 17():6131-6155. PubMed ID: 36514378
[TBL] [Abstract][Full Text] [Related]
40. Lipid Nanoparticles for mRNA Delivery to Enhance Cancer Immunotherapy.
Wang HL; Wang ZG; Liu SL
Molecules; 2022 Aug; 27(17):. PubMed ID: 36080373
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
